As Biogen aims to grow sales of postpartum depression drug Zurzuvae, it’s turning to well-funded telehealth company Talkiatry to boost awareness of and care for the often overlooked condition.
Under the deal, Talkiatry, which recently raised $130 million and employs over 350 psychiatrists, created a new landing page on its website with information about postpartum depression. From there, visitors can take an intake assessment that funnels them into Talkiatry’s care programs. The Zurzuvae website will include a link to the landing page. The terms of the deal were not disclosed.
According to the CDC, 1 in 8 people experience postpartum depression after giving birth, with symptoms that may include sadness or guilt or a desire to harm oneself. Many do not receive adequate care, with potential long-term impacts on the health of parents and newborns.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
